Stay updated on Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial
Sign up to get notified when there's something new on the Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial page.

Latest updates to the Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial page
- Check2 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2; the Back to Top element was removed.SummaryDifference0.1%
- Check9 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.1%
- Check16 days agoChange DetectedThe webpage has undergone significant updates, including the addition of new facility names and locations, as well as a publication related to dupilumab, while several previous location entries and drug information have been removed.SummaryDifference5%
- Check24 days agoChange DetectedThe web page has been updated to reflect the latest results of a study on dupilumab for chronic spontaneous urticaria (CSU), including new efficacy data and participant demographics. Notably, the number of study locations has decreased from 101 to 98, and the results posting date has been updated to August 20, 2025.SummaryDifference100%
- Check31 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check38 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
Stay in the know with updates to Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial page.